Congenital Cmv
Conditions
Brief summary
This is an observational, prospective/retrospective multicentre, cohort study of children diagnosed with cCMV. This study will contribute to a wider study also recruiting participants in Europe and other countries worldwide. No investigations or treatment will be carried out that are not part of routine clinical practice. Infants with cCMV are routinely followed up from an infectious diseases, audiology, ophthalmology and neurodevelopmental perspective until approximately 6 years of age, or longer if there are ongoing issues. Some children will be retrospectively diagnosed with cCMV in later childhood. Recruitment can be from any centre that manages these patients and has agreed to participate in the study.
Detailed description
Cytomegalovirus (CMV) is the most frequent cause of congenital infection worldwide, occurring in 0.2-2% of live births. It is also the most frequent cause of non-genetic hearing loss, and an important cause of neurodevelopmental delay. Clinical diagnosis of maternal infection during pregnancy is unreliable in most patients and laboratory diagnosis can be challenging, especially in non-primary infections. Screening of congenital CMV infection (cCMV) in newborns is not recommended in most countries and only targeted screening is performed in some cases (children who fail hearing screening or with abnormalities compatible with cCMV in physical exams). The main focus of the study is to identify patient and treatment characteristics that are associated with outcome. This will allow improved patient care in the future.
Interventions
None listed
Sponsors
European Society for Paediatric Infectious Diseases
St George's, University of London
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 10 Years
Healthy volunteers
No
Inclusion criteria
Patients of either sex that have been diagnosed with cCMV infection: * Through confirmed detection of CMV in urine or saliva, by CMV-DNA PCR (or viral culture / Shell-vial) and/or CMV detection in blood or CSF by PCR within the first 21 days of life. * Children with cCMV retrospectively diagnosis by positive CMV-DNA PCR in dried blood spots (DBS), collected within 21 days of life. * Diagnosed by positive CMV-DNA PCR in dried umbilical cord blood or donated/stored umbilical cord blood sample * Children whose parents give their informed consent to participate in the study * Age less than 11 years old
Exclusion criteria
* Refusal to sign written informed consent of parents/ legal guardian.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measuring cases of cCMV in the UK | 15 years | To analyze the epidemiology of children born with cCMV |
| Clinical characteristics | 15 years | To analyze the clinical characteristic of children born with cCMV (measure is number of participants with hearing loss, retinitis, neurological abnormalities, skin rashes, or hepatosplenomegaly) |
| To evaluate risk factors in children with cCMV for long term sequelae | 15 years | To measure the number of cases with abnormal brain imaging (cranial USS or MRI), hearing loss, retinitis or anaemia, leucopenia, thrombocytopenia, renal function or liver abnormalities at diagnosis |
| Adverse events | 15 years | To document adverse events of different treatment strategies |
| To evaluate the prognostic value of microbiological variables | 15 years | To measure the urine CMV viral load in cases at diagnosis who develop hearing loss |
| To evaluate the prognostic value of image findings | 15 years | To measure the number of cases who have abnormal brain imaging (cranial USS or MRI) at diagnosis and develop hearing loss |
| To evaluate associated outcomes with different treatment strategies | 15 years | To measure the number of cases treated with valganciclovir and the number of treated cases who need a treatment break |
Countries
United Kingdom
Contacts
Primary ContactSana Ibrahim, BSc
Outcome results
None listed